Raptor Pharmaceutical Corp. Reports Third Quarter 2015 Financial Results and Provides Corporate Update
05 nov. 2015 16h04 HE
|
Raptor Pharmaceutical Inc
Record PROCYSBI® Product Sales of $25.8 Million
Raptor Raises 2015 PROCYSBI Revenue Guidance to $90-$95 Million
Company to Host Conference Call and Webcast Today at 4:30 p.m. EST
NOVATO,...
Raptor Pharmaceutical to Hold Third Quarter 2015 Financial Results Conference Call and Webcast on Thursday, November 5, 2015, at 4:30 p.m. ET
29 oct. 2015 16h05 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release third quarter 2015 financial results on Thursday, November 5,...
Raptor Pharmaceutical Completes Acquisition of Quinsair(TM)
05 oct. 2015 07h05 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has completed the acquisition of Quinsair™ (levofloxacin inhalation solution)...
Raptor Pharmaceutical to Participate in the Leerink Partners 4th Annual Rare Disease Roundtable
23 sept. 2015 07h30 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference:
Julie Anne Smith,...
Raptor Pharmaceutical Provides Topline Results From Phase 2b CyNCh Study Evaluating RP103 in Pediatric Nonalcoholic Steatohepatitis
14 sept. 2015 07h05 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced topline results from the Phase 2b CyNCh study, which did not meet its primary endpoint of...
Raptor Pharmaceutical Corp. Expands Rare Disease Portfolio With the Acquisition of Quinsair(TM)
20 août 2015 17h16 HE
|
Raptor Pharmaceutical Inc
First Inhaled Fluoroquinolone Therapy for Patients with Cystic Fibrosis
Approval Received in the European Union and Canada
Expansion of Pipeline with Multiple Late-Stage Orphan Indication...
Raptor Pharmaceutical Voted a "Best Places to Work" Company in the North San Francisco Bay Area
20 août 2015 14h46 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 20, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) announced today that it was named among the top workplaces in the North Bay in the 10th Annual North Bay...
Raptor Pharmaceutical Receives FDA Approval of Expanded Label for PROCYSBI(R) to Treat Children Aged 2-6 Years With Nephropathic Cystinosis
17 août 2015 07h05 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 17, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ:RPTP) today announced that the U.S. Food and Drug Administration (FDA) approved the expanded use of PROCYSBI®...
Raptor Pharmaceutical Corp. Reports Second Quarter 2015 Financial Results and Provides Corporate Update
06 août 2015 16h04 HE
|
Raptor Pharmaceutical Inc
PROCYSBI® Product Sales Increased 43% Year over Year to $23.3 Million in Second Quarter
Balance Sheet Strengthened with over $220 Million in Cash, Cash Equivalents and Short-Term Investments...
Raptor Pharmaceutical to Hold Second Quarter 2015 Financial Results Conference Call and Webcast on Thursday, August 6, 2015, at 4:30 p.m. EDT
30 juil. 2015 07h30 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., July 30, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release second quarter 2015 financial results on Thursday, August 6,...